High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40kd) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin

被引：20
|
作者：
Nelson, D. [1 ]
Pockros, P. J. [2 ]
Godofsky, E. [3 ]
Rodriguez-Torres, M. [4 ]
Everson, G. [5 ]
Fried, M. [6 ]
Ghalib, R. [7 ]
Harrison, S. [8 ]
Nyberg, L. [9 ]
Shiffman, M. [10 ]
Chan, A.
Hill, G.
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Scripps Clin, La Jolla, CA 92037 USA
[3] Univ Hepatitis Ctr Bach & Godofsky, Bradenton, FL USA
[4] Fdn Invest Diego, Santurce, PR USA
[5] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[6] Univ N Carolina, Chapel Hill, NC USA
[7] Dallas Methodist Hosp, Liver Inst, Dallas, TX USA
[8] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
[9] Kaiser Permanente, San Diego, CA USA
[10] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60995-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
993
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [31] Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany -: A contribution to health care research
    Zehnter, E
    Mauss, S
    John, C
    Heyne, R
    Möller, B
    Bokemeyer, B
    Moog, G
    Alshuth, U
    Hüppe, D
    HEPATOLOGY, 2005, 42 (04) : 683A - 683A
  • [32] Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Lee, SS
    Heathcote, EJ
    Reddy, KR
    Zeuzem, S
    Fried, MW
    Wright, TL
    Pockros, PJ
    Häussinger, D
    Smith, CI
    Lin, A
    Pappas, SC
    JOURNAL OF HEPATOLOGY, 2002, 37 (04) : 500 - 506
  • [33] Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin
    Reau, Nancy
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Fried, Michael W.
    Jensen, Donald M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08): : 1981 - 1988
  • [34] Treatment with peginterferon alfa-2a (40 KD) (PEGASYS®) plus ribavirin (COPEGUS®) for just 24 weeks is sufficient in HCV genotype 1 or 4 'super-responders'
    Ferenci, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A121 - A121
  • [35] Peginterferon alfa-2a (40KD) with or without ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Preliminary report of a randomized study.
    Petrolati, A
    Lionetti, R
    Donato, F
    Merli, M
    Burra, P
    Angeli, P
    Strazzabosco, M
    Tisone, G
    Angelico, M
    JOURNAL OF HEPATOLOGY, 2004, 40 : 38 - 38
  • [36] Optimized virological response in genotype 4 chronic hepatitis C patients treated with peginterferon alfa-2A (40KD) (PEGASYS®) in combination with ribavirin (RBV).
    Diago, M
    Hadziyannis, SJ
    Dunant, H
    Bodenheimer, H
    Hassanein, T
    Uchman, S
    Marcellin, P
    Ramadori, G
    Delwaide, J
    Sedarati, F
    HEPATOLOGY, 2002, 36 (04) : 364A - 364A
  • [37] High response rates with peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in Japanese non-responders or relapsers to conventional interferon
    Izumi, Namiki
    Iino, Shiro
    Okuno, Tadao
    Omata, Massao
    Kiyosawa, Kendo
    Kumada, Hiromitsu
    Hayashi, Norio
    Yamada, Gotaro
    Sakai, Takahiro
    GASTROENTEROLOGY, 2006, 130 (04) : A841 - A842
  • [38] Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years
    Meyer, Ulrike
    Zehnter, Elmar
    Mauss, Stefan
    Boeker, Klaus
    Lutz, Thomas
    Racky, Stefan
    Schmidt, Wolfgang
    Ullrich, Rainer
    Sbrijer, Innessa
    Heyne, Renate
    Schober, Andreas
    John, Christine
    Hey, Karl-Heinz
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Moeller, Bernd
    Pape, Stefan
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2007, 132 (04) : A790 - A791
  • [39] Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in HCV patients with complete cirrhosis (Knodell score F4)
    Bruno, Savino
    Maisonneuve, Patrick
    Pockros, Paul J.
    Sarracino, Massimo
    Diagos, Moises
    Zeuzem, Stefan
    Rizzetto, Mario
    Marcellin, Patrick
    Hadziyannis, Stephanos J.
    HEPATOLOGY, 2006, 44 (04) : 332A - 333A
  • [40] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
12345